<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02208713</url>
  </required_header>
  <id_info>
    <org_study_id>Royan-Nerve-007</org_study_id>
    <nct_id>NCT02208713</nct_id>
  </id_info>
  <brief_title>Intramuscular Transplantation of Muscle Derived Stem Cell and Adipose Derived Mesenchymal Stem Cells in Patients With Facioscapulohumeral Dystrophy (FSHD)</brief_title>
  <official_title>Intramuscular Transplantation of Autologous Muscle Derived Stem Cell(MDSC) and Adipose Derived Mesenchymal Stem Cells (AD-MSC) in Patients With Facioscapulohumeral Dystrophy (FSHD), Phase I Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Facioscapulohumeral Dystrophy is a Autosomal dominant inherited dystrophy with the prevalence
      of 1:20,000 and it is the third most common dystrophy after the dystrophinopathies and
      myotonic dystrophy. The symptoms including: Pain, facial weakness, scapular fixator, humeral,
      truncal, pelvic girdle and lower-extremity weakness, High frequency hearing loss, Retinal
      telangiectasia . The existing treatments are not effective so, cell therapy is a new hope to
      improve patients' quality of life. Therefore, We design this clinical trial to evaluate the
      safety and feasibility of stem cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, we select 15 patients with FSHD based on eligibility criteria. All the
      patients underwent physical examination, laboratory evaluations, EMG-NCV, muscle sonography
      and muscle MRI. Then, a sample of patient's muscle is taken from Biceps Femoralis to isolate
      and culture of MDSC. The AD-MSC is prepared from Royan Adipose Tissue Bank. The patient is
      admitted in general hospital, and the cell suspensions are injected into biceps, triceps and
      trapezoids muscles by neurologists. After transplantation, the patients will be under
      observation for 5 hours and will be discharged if no side effect happen. All the patients
      will be followed at 1,2,4,6 and 12 months after cell injection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myalsia</measure>
    <time_frame>1month</time_frame>
    <description>Evaluation the presence of myalsia 1month after cell injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass formation</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation the probability of mass formation 6 months after cell injection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematoma</measure>
    <time_frame>1 month</time_frame>
    <description>Evaluation the presence of hematoma 1 month after injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle bulk</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation the muscle bulk changes with sonography and MRI 6 months after transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CPK</measure>
    <time_frame>1month</time_frame>
    <description>Evaluation the decrease of CPK 1 month after cell transplantation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Dystrophy</condition>
  <arm_group>
    <arm_group_label>Stem cell recipient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients with FSHD who underwent muscle derived stem cell and Adipose derived mesenchymal stem cell with intramuscular injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intramuscular injection</intervention_name>
    <description>Intramuscular injection of stem cells in patients with FSHD.</description>
    <arm_group_label>Stem cell recipient</arm_group_label>
    <other_name>Intramuscular cell transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18-50

          2. Both gender

          3. Weakness of face muscle

          4. FSHD phenotype positive

          5. Genetic Test confirmation for FSHD

        Exclusion Criteria:

          1. Co - morbidities: Heart &amp; respiratory diseases,malignancy, rheumatologic disorders

          2. Progressive form of disease

          3. Not able to sign the consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Gourabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nasser Aghdami, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Head of Department of Regenerative Medicine &amp; Cell therapy center of Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahdi Vahid Dastjerdi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Scientific Board of BouAli Hospital, Azad University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leila Arab, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Regenerative Medicine &amp; cell therapy of Royan Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nasser Aghdami, MD,PhD</last_name>
    <phone>(+98)23562000</phone>
    <phone_ext>516</phone_ext>
    <email>nasser.aghdami@royaninstitute.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leila Arab, MD</last_name>
    <phone>(+98)23562000</phone>
    <phone_ext>414</phone_ext>
    <email>Leara91@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nasser Aghdami, MD,PhD</last_name>
      <phone>(+98)212356000</phone>
      <phone_ext>516</phone_ext>
      <email>nasser.aghdami@royaninstitute.org</email>
    </contact>
    <contact_backup>
      <last_name>Leila Arab, MD</last_name>
      <phone>(+98)23562000</phone>
      <phone_ext>414</phone_ext>
      <email>Leara91@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Neda Jarooghi, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tina Bolourieh, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fatemeh Abbasi, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://Royaninstitute.org</url>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2014</study_first_submitted>
  <study_first_submitted_qc>August 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2014</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FSHD muscle derived stem cell adipose derived mesenchymal stem cell intramuscular injection</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

